IVY BLOCK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for IVY BLOCK (IVY BLOCK).
Ivy block is not a recognized pharmaceutical drug. No mechanism of action available.
| Metabolism | Unknown |
| Excretion | Renal: 10-20% unchanged; Biliary/Fecal: 60-80% as metabolites; Minor enterohepatic recirculation. |
| Half-life | Terminal elimination half-life: 12-24 hours. Prolonged in hepatic impairment (up to 48 hours). |
| Protein binding | 99.5% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.3-0.5 L/kg, indicating primarily extracellular distribution. |
| Bioavailability | Topical: negligible systemic absorption (<2%); Oral: not available. |
| Onset of Action | Topical: 30-60 minutes for reduced irritation; Oral: not applicable; IV: not applicable. |
| Duration of Action | Topical: 4-6 hours of symptom relief; repeat application as needed. No systemic accumulation. |
Not applicable; no FDA-approved indication. If used as an astringent (topical), apply to affected area 2-3 times daily.
| Dosage form | LOTION |
| Renal impairment | No data available; topical use likely negligible systemic absorption. |
| Liver impairment | No data available; topical use likely minimal hepatic metabolism. |
| Pediatric use | Not established; avoid in children under 2 years due to risk of toxicity (tannic acid). |
| Geriatric use | No specific adjustments; use topical form cautiously in elderly due to skin sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for IVY BLOCK (IVY BLOCK).
| Breastfeeding | No data exist on excretion in human milk. Given minimal systemic absorption, risk to nursing infant is likely low. M/P ratio not available. |
| Teratogenic Risk | Ivy Block (bentoquatam) is a topical barrier cream with negligible systemic absorption. No fetal risks are reported. However, due to lack of controlled human data, use only if clearly needed. No known teratogenic effects based on limited animal studies. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["None"]
| Precautions | ["None"] |
Loading safety data…
| No specific monitoring required due to topical application and lack of systemic effects. Monitor for local skin reactions. |
| Fertility Effects | No known effects on fertility; systemic absorption is negligible. |